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eToxPred: a machine learning-based
approach to estimate the toxicity of drug
candidates
Limeng Pu1, Misagh Naderi2, Tairan Liu3, Hsiao-Chun Wu1, Supratik Mukhopadhyay4 and Michal Brylinski2,5*

Abstract
Background: The efficiency of drug development defined as a number of successfully launched new
pharmaceuticals normalized by financial investments has significantly declined. Nonetheless, recent advances in
high-throughput experimental techniques and computational modeling promise reductions in the costs and
development times required to bring new drugs to market. The prediction of toxicity of drug candidates is one of
the important components of modern drug discovery.
Results: In this work, we describe eToxPred, a new approach to reliably estimate the toxicity and synthetic
accessibility of small organic compounds. eToxPred employs machine learning algorithms trained on molecular
fingerprints to evaluate drug candidates. The performance is assessed against multiple datasets containing known
drugs, potentially hazardous chemicals, natural products, and synthetic bioactive compounds. Encouragingly,
eToxPred predicts the synthetic accessibility with the mean square error of only 4% and the toxicity with the
accuracy of as high as 72%.
Conclusions: eToxPred can be incorporated into protocols to construct custom libraries for virtual screening in
order to filter out those drug candidates that are potentially toxic or would be difficult to synthesize. It is freely
available as a stand-alone software at https://github.com/pulimeng/etoxpred.
Keywords: Virtual screening, Synthetic accessibility, Toxicity, Machine learning, Deep belief network, Extremely
randomized trees

Background
Drug discovery is an immensely expensive and time-consuming process posing a number of formidable challenges. To develop a new drug requires 6–12 years and
costs as much as $2.6 billion [1, 2]. These expenses do
not include the costs of basic research at the universities
focused on the identification of molecular targets, and
the development of research methods and technologies.
Despite this cumbersome discovery process, the pharmaceutical industry is still regarded as highly profitable
because the expenses are eventually accounted for in the
market price of new therapeutics. Although, a breakdown
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of the overall capitalized costs shows that the clinical
period costing $1.5 billion is economically the most critical factor, the expenditures of the pre-human phase aggregate to $1.1 billion [1]. Thus, technological advances in
discovery research and preclinical development could potentially lower the costs of bringing a new drug to the
market.
Computer-aided drug discovery (CADD) holds a significant promise to reduce the costs and speed up the development of lead candidates at the outset of drug discovery [3].
Powered by continuous advances in computer technologies,
CADD employing virtual screening (VS) allows identifying
hit compounds from large databases of drug-like molecules
much faster than traditional approaches. CADD strategies
include ligand- and structure-based drug design, lead
optimization, and the comprehensive evaluation of absorption, distribution, metabolism, excretion, and toxicity
(ADMET) parameters [4]. Ligand-based drug design
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(LBDD) leverages the spatial information and physicochemical features extracted from known bioactives against a
given target protein to design and optimize new compounds for the same target [5]. VS employing features provided by pharmacophore modeling [6] and quantitative
structure-activity relationship (QSAR) analysis [7] can be
performed in order to identify potentially active compounds. Although the capabilities of the traditional LBDD
to discover new classes of leads may be limited, recent
advances in generating targeted virtual chemical libraries by
combinatorial chemistry methods considerably extend the
application of LBDD methods [8–10]. Captopril, an
angiotensin-converting enzyme inhibitor, was one of the
first success stories of LBDD, which was considered a revolutionary concept in 1970s compared to conventional
methods [11].
Although the combination of pharmacophore modeling, QSAR, and VS techniques has been demonstrated
to be valuable in the absence of the protein structure
data [12, 13], the three-dimensional (3D) information on
the target protein allows employing structure-based drug
design (SBDD) [14] in CADD. Foremost SBDD methods
include molecular docking [15], molecular dynamics
[16], receptor-based VS [17], and the de novo design of
active compounds [18]. Molecular docking is widely
used in CADD to predict the preferable orientation of a
drug molecule in the target binding pocket by finding
the lowest energy configuration of the protein-ligand
system. It is often employed to conduct receptor-based
VS whose goal is to identify in a large library of candidate
molecules those compounds that best fit the target binding site. VS performed with high-performance computing
machines renders docking programs such as AutoDock
Vina [19], rDock [20], Glide [21], and FlexX [22] capable
to search through millions of compounds in a matter of
days or even hours. A potent, pyrazole-based inhibitor of
the transforming growth factor-β type I receptor kinase
exemplifies benefits of utilizing receptor-based VS to discover leads. This inhibitor has been independently discovered with the computational, shape-based screening of
200,000 compounds [23] as well as the traditional enzyme
and cell-based high-throughput screening of a large library
of molecules [24].
In addition to LBDD and SBDD, toxicity prediction is
an increasingly important component of modern CADD,
especially considering that the collections of virtual molecules for VS may comprise tens of millions of untested
compounds. Methods to predict toxicity aim at identifying
undesirable or adverse effects of certain chemicals on
humans, animals, plants, or the environment. Conventional approaches to evaluate toxicity profiles employing
animal tests are constrained by time, costs, and ethical
considerations. On that account, fast and inexpensive
computational approaches are often employed at first in
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order to eliminate potentially toxic molecules and reduce
the number of experimental tests that need to be conducted. For instance, a blockage of the human Ether-à-go-go-Related Gene (hERG) potassium ion channels by a
surprisingly diverse group of drugs can induce lethal cardiac arrhythmia [25]. Therefore, the effective identification
of putative hERG blockers and non-blockers in chemical
libraries plays an important role in the cardiotoxicity prediction. A recently developed method, Pred-hERG, estimates the cardiac toxicity with a set of features based on
statistically significant and externally predictive QSAR
models of the hERG blockage [26]. Pred-hERG employs a
binary model, a multi-class model, and the probability
maps of atomic contribution, which are combined for the
final prediction. Encouragingly, Pred-hERG achieves a
high correct classification rate of 0.8 and a multi-class accuracy of 0.7.
Another example is chemTox (http://www.cyprotex.com/
insilico/physiological_modelling/chemtox) predicting key
toxicity parameters, the Ames mutagenicity [27] and the
median lethal dose (LD50) following intravenous and oral
administration, as well as the aqueous solubility. chemTox
employs molecular descriptors generated directly from
chemical structures to construct quantitative-structure
property relationships (QSPR) models. Since this method
requires a set of specific descriptors to generate QSPR
models for a particular type of toxicity, it may not be suitable to evaluate a broadly defined toxicity and drug
side-effects in general. A similar method, ProTox, predicts
rodent oral toxicity based on the analysis of toxic fragments
present in compounds with known LD50 values [28]. ProTox additionally evaluates possible targets associated with
adverse drug reactions and the underlying toxicity mechanisms with the collection of protein-ligand pharmacophores, called toxicophores. This tool was reported to
outperform the commercial software TOPKAT (TOxicity
Prediction by Komputer Assisted Technology, http://accelrys.com/products/collaborative-science/biovia-discovery-studio/qsar-admet-and-predictive-toxicology.html) against a
diverse external validation set, with the sensitivity, specificity and precision of 0.76, 0.95 and 0.75, respectively. Other
techniques to predict toxicity utilize various features such
as fingerprints, physicochemical properties, and pharmacophore models to build predictive dose- and time-response
models [29].
The Tox21 Data Challenge 2014 (https://tripod.nih.gov/
tox21/challenge/index.jsp) has been conducted to assess a
number of methods predicting how chemical compounds
disrupt biological pathways in ways that may result in toxic
effects. In this challenge, the chemical structure data for
12,707 compounds were provided in order to evaluate the
capabilities of modern computational approaches to identify those environmental chemicals and drugs that are of
the greatest potential concern to human health. DeepTox
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[30] was the best performing methods in the Tox21 Data
Challenge winning the grand challenge, the nuclear receptor panel, the stress response panel, and six single assays.
This algorithm employs the normalized chemical representations of compounds to compute a large number of descriptors as an input to machine learning. Models in
DeepTox are first trained and evaluated, and then the most
accurate models are combined into ensembles ultimately
used to predict the toxicity of new compounds. DeepTox
was reported to outperform deep neural networks (DNNs)
[31], support vector machines (SVMs) [32], random forests
(RF) [33], and elastic nets [34].
In this communication, we describe eToxPred, a new
method to predict the synthetic accessibility and the toxicity of molecules in a more general manner. In contrast
to other approaches employing manually-crafted descriptors, eToxPred implements a generic model to estimate
the toxicity directly from the molecular fingerprints of
chemical compounds. Consequently, it may be more effective against highly diverse and heterogeneous datasets.
Machine learning models in eToxPred are trained and
cross-validated against a number of datasets comprising
known drugs, potentially hazardous chemicals, natural
products, and synthetic bioactive compounds. We also
conduct a comprehensive analysis of the chemical composition of toxic and non-toxic substances. Overall,
eToxPred quite effectively estimates the synthetic accessibility and the toxicity of small organic compounds directly
from their molecular fingerprints. As the primary
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application, this technique can be incorporated into
high-throughput pipelines constructing custom libraries
for virtual screening, such as that based on eMolFrag [9]
and eSynth [10], to eliminate from CADD those drug candidates that are potentially toxic or would be difficult to
synthesize.

Implementation
Machine learning algorithms

Numerous machine learning-based techniques have been
developed to reveal complex relations between chemical
entities and their biological targets [35]. In Fig. 1, we
briefly present the concepts and the overall implementation of machine learning classifiers employed in this
study. The first algorithm is the Restricted Boltzmann
Machine (RBM), an undirected graphical model with a
visible input layer and a hidden layer. In contrast to the
unrestricted Boltzmann Machine, in which all nodes are
connected to one another (Fig. 1A) [36], all inter-layer
units in the RBM are fully connected, while there are no
intra-layer connections (Fig. 1B) [37]. The RBM is an
energy-based model capturing dependencies between
variables by assigning an “energy” value to each configuration. The RBM is trained by balancing the probability
of various regions of the state space, viz. the energy of
those regions with a high probability is reduced, with the
simultaneous increase in the energy of low-probability
regions. The training process involves the optimization
of the weight vector through Gibbs sampling [38].

Fig. 1 Schematics of various machine learning classifiers. (a) A two-layered Boltzmann Machine with 3 hidden nodes h and 2 visible nodes v.
Nodes are fully connected. (b) A Restricted Boltzmann Machine (RBM) with the same nodes as in A. Nodes belonging to the same layer are not
connected. (c) A Deep Belief Network with a visible layer V and 3 hidden layers H. Individual layers correspond to RBMs that are stacked against
one another. (d) A Random Forest with 3 trees T. For a given instance, each tree predicts a class based on a subset of the input set. The final
class assignment is obtained by the majority voting of individual trees
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The Deep Belief Network (DBN) is a generative probabilistic model built on multiple RBM units stacked
against each other, where the hidden layer of an unsupervised RBM serves as the visible layer for the next
sub-network (Fig. 1C) [39]. This architecture allows for
a fast, layer-by-layer training, during which the contrastive divergence algorithm [40] is employed to learn a
layer of features from the visible units starting from the
lowest visible layer. Subsequently, the activations of previously trained features are treated as a visible unit to
learn the abstractions of features in the successive hidden layer. The whole DBN is trained when the learning
procedure for the final hidden layer is completed. It is
noteworthy that DBNs are first effective deep learning
algorithms capable of extracting a deep hierarchical representation of the training data [41].
In this study, we utilize a DBN implemented in Python
with Theano and CUDA to support Graphics Processing
Units (GPUs) [42]. The SAscore is predicted with a DBN
architecture consisting of a visible layer corresponding
to a 1024-bit Daylight fingerprint (http://www.daylight.com) and three hidden layers having 512, 128, and 32
nodes (Fig. 1C). The L2 regularization is employed to reduce the risk of overfitting. The DBN employs an adaptive learning rate decay with an initial learning rate, a
decay rate, mini-batch size, the number of pre-training
epochs, and the number of fine-tuning epochs of 0.01,
0.0001, 100, 20, and 1000, respectively.
Finally, the Extremely Randomized Trees, or Extra
Trees (ET), algorithm [43] is used to predict the toxicity
of drug candidates (Fig. 1D). Here, we employ a simpler
algorithm because classification is generally less complex
than regression. Classical random decision forests construct an ensemble of unpruned decision trees predicting
the value of a target variable based on several input variables [44]. Briefly, a tree is trained by recursively partitioning the source set into subsets based on an attribute
value test. The dataset fits well the decision tree model
because each feature takes a binary value. The recursion
is completed when either the subset at a node has an invariant target value or when the Gini impurity reaches a
certain threshold [45]. The output class from a decision
forest is simply the mode of the classes of the individual
trees. The ET classifier is constructed by adding a randomized top-down splitting procedure in the tree
learner. In contrast to other tree-based methods commonly employing a bootstrap replica technique, ET splits
nodes by randomly choosing both attributes and
cut-points, as well as it uses the whole learning sample
to grow the trees. Random decision forests, including
ET, are generally devoid of problems caused by overfitting to the training set because the ensemble of trees reduces model complexity leading to a classifier with a low
variance. In addition, with a proper parameter tuning,
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the randomization procedure in ET can help achieve robust performance even for small training datasets.
The ET classifier used in this study is implemented in
Python. We found empirically that the optimal performance in terms of the out-of-bag error is reached at 500
trees and adding more trees causes overfitting and increases the computational complexity. The number of
features to be randomly drawn from the 1024-bit input
vector is log2 1024 = 10. The maximum depth of a tree
is 70 with minimum numbers of 3 and 19 samples to
create and split a leaf node, respectively.
Datasets

Table 1 presents compound datasets are employed in
this study. The first two sets, the Nuclei of Bioassays,
Ecophysiology and Biosynthesis of Natural Products
(NuBBE), and the Universal Natural Products Database
(UNPD), are collections of natural products. NuBBE is a
virtual database of natural products and derivatives from
the Brazilian biodiversity [46], whereas UNPD is a general resource of natural products created primarily for
virtual screening and network pharmacology [47]. Removing the redundancy at a Tanimoto coefficient (TC)
[48] of 0.8 with the SUBSET [49] program resulted in
1008 NuBBE and 81,372 UNPD molecules. In addition
to natural products, we compiled a non-redundant set of
mostly synthetic bioactive compounds from the Database of Useful Decoys, Extended (DUD-E) database [50]
by selecting 17,499 active molecules against 101 pharmacologically relevant targets.
The next two sets, FDA-approved and Kyoto
Encyclopedia of Genes and Genomes (KEGG) Drug,
comprise molecules approved by regulatory agencies,
which possess acceptable risk versus benefit ratios. Although these molecules may still cause adverse drug reactions, we refer to them as non-toxic because of their
relatively high therapeutic indices. FDA-approved drugs
were obtained from the DrugBank database, a widely
used cheminformatics resource providing comprehensive
information on known drugs and their molecular targets
[51]. The KEGG-Drug resource contains drugs approved
in Japan, United States, and Europe, annotated with the
information on their targets, metabolizing enzymes, and
molecular interactions [52]. Removing the chemical redundancy from both datasets yielded 1515 FDA-approved
and 3682 KEGG-Drug compounds.
Two counter-datasets, TOXNET and the Toxin and
Toxin Target Database (T3DB), contain compounds indicated to be toxic. The former resource maintained by the
National Library of Medicine provides databases on toxicology, hazardous chemicals, environmental health, and
toxic releases [53]. Here, we use the Hazardous Substances Data Bank focusing on the toxicology of potentially hazardous chemicals. T3DB houses detailed toxicity
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Table 1 Compound datasets used to evaluate the performance of eToxPred. These non-redundant sets are employed to train and
test SAscore, Tox-score, and specific toxicities
Dataset

Size

Usage

Description

NuBBE

1008

Train/test (SAscore)

Natural products and derivatives from the Brazilian biodiversity

UNPD

81,372

Train/test (SAscore)

Diverse collection of natural products

DUD-E (actives)

17,499

Train/test (SAscore)

Mostly synthetic bioactive compounds against 102 protein targets

FDA-approved

1515

Train/test (SAscore)
Train (Tox-score)

FDA approved drugs from DrugBank

KEGG-Drug

3682

Test (Tox-score)

Drugs approved in Japan, United States, and Europe

TOXNET

3035

Train (Tox-score)

Potentially hazardous chemicals

T3DB

1283

Test (Tox-score)

Collection of pollutants, pesticides, drugs, and food toxins

TCM

5883

Test (SAscore, Tox-score, unlabeled)

Traditional Chinese medicines

CP

1401

Train/test (specific toxicity)

Carcinogenic compounds tested in rodents

CD

1571

Train/test (specific toxicity)

Cardiotoxic compounds tested against hERG potassium channel

ED

17,059

Train/test (specific toxicity)

Endocrine disrupting compounds tested against androgen and
estrogen receptors

AO

12,612

Train/test (specific toxicity)

Toxins from various sources annotated with acute oral toxicity

data in terms of chemical properties, molecular and cellular interactions, and medical information, for a number of
pollutants, pesticides, drugs, and food toxins [54]. These
data are extracted from multiple sources including other
databases, government documents, books, and scientific literature. The non-redundant sets of TOXNET and T3DB
contain 3035 and 1283 toxic compounds, respectively.
As an independent set, we employ the Traditional
Chinese Medicine (TCM) Database@Taiwan, currently
the largest and most comprehensive small molecule
database on traditional Chinese medicine for virtual
screening [55]. TCM is based on information collected
from Chinese medical texts and scientific publications
for 453 different herbs, animal products, and minerals.
From the original dataset, we first selected molecules
with a molecular weight in the range of 100–600 Da,
and then removed redundancy at a TC of 0.8, producing
a set of 5883 unique TCM compounds.
Finally, we use four datasets to evaluate the prediction of
specific toxicities. Compounds causing cancer in high dose
tests were obtained from the Carcinogenicity Potency (CP)
database [56]. These data are labeled based on series of experiments carried out on rodents considering different tissues of the subjects. A chemical is deemed toxic if it caused
tumor growth in at least one tissue specific experiment.
The CP set comprises 796 toxic and 605 non-toxic compounds. The cardiotoxicity (CD) dataset contains 1571
molecules characterized with bioassay against human
ether-a-go-go related gene (hERG) potassium channel.
hERG channel blockade induces lethal arrhythmia causing
a life-threatening symptom [57]. The CD set includes 350
toxic compounds with an IC50 of < 1 μM [58]. The endocrine disruption (ED) dataset is prepared based on the bioassay data for androgen and estrogen receptors taken from

the Tox21 Data Challenge. Endocrine disrupting chemicals
interfere with the normal functions of endogenous hormones causing metabolic and reproductive disorders, the
dysfunction of neuronal and immune systems, and cancer
growth [59]. The ED set contains 1317 toxic and 15,742
non-toxic compounds. The last specific dataset is focused
on the acute oral toxicity (AO). Among 12,612 molecules
with LD50 data provided by the SuperToxic database [60],
7392 compounds are labeled as toxic with a LD50 of < 500
mg kg− 1. It is important to note that since LD50 is not indicative of non-lethal toxic effects, a chemical with a high
LD50 may still cause adverse reactions at small doses.
Model training, cross-validation, and evaluation

Input data to machine learning models are 1024-bit Daylight fingerprints constructed for dataset compounds with
Open Babel [61]. The reference SAscore values are computed with an exact approach that combines the
fragment-based score representing the “historical synthetic
knowledge” with the complexity-based score penalizing the
presence of ring systems, such as spiro and fused rings,
multiple stereo centers, and macrocycles [62]. The
DBN-based predictor of the SAscore was trained and
cross-validated against NuBBE, UNPD, FDA-approved, and
DUD-E-active datasets. Cross-validation is a common
technique used in statistical learning to evaluate the
generalization of a trained model [63]. In a k-fold
cross-validation protocol, one first divides the dataset into k
different subsets and then the first subset is used as a validation set for a model trained on the remaining k – 1 subsets. This procedure is repeated k times employing different
subsets as the validation set. Averaging the performance
obtained for all k subsets yields the overall performance
and estimates the validation error of the model. In this
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work, the SAscore predictor is evaluated with a 5-fold
cross-validation protocol, which was empirically demonstrated to be sufficient for most applications [64].
The Tox-score prediction is conducted with a binary,
ET-based classifier. The training and cross-validation are
carried out for the FDA-approved dataset used as positive (non-toxic) instances and the TOXNET dataset used
as negative (toxic) instances. Subsequently, the toxicity
predictor is trained on the entire FDA-approved/TOXNET dataset and then independently tested against the
KEGG-Drug (positive, non-toxic) and T3DB (negative,
toxic) sets. In addition, the capability of the classifier to
predict specific toxicities is assessed against CP, CD, ED,
and AO datasets. Similar to the SAscore predictor, a
5-fold cross-validation protocol is employed to rigorously evaluate the performance of the toxicity classifier.
Finally, both machine learning predictors of SAscore
and Tox-score are applied to the TCM dataset.
The performance of eToxPred is assessed with several
metrics derived from the confusion matrix, the accuracy
(ACC), the sensitivity or true positive rate (TPR), and
the fall-out or false positive rate (FPR):

ACC ¼

TP þ TN
TP þ FP þ TN þ FN

ð1Þ

TPR ¼

TP
TP þ FN

ð2Þ

FP
FPR ¼
FP þ TN

ð3Þ

where TP is the number of true positives. i.e.
non-toxic compounds classified as non-toxic, and TN is
the number of true negatives, i.e. toxic compounds classified as toxic. FP and FN are the numbers of over- and
under-predicted non-toxic molecules, respectively.
In addition, we assess the overall quality of a binary
classifier with the Matthews correlation coefficient
(MCC) [65] and the Receiver Operating Characteristic
(ROC) analysis. The MCC is generally regarded as a
well-balanced measure ranging from − 1 (anti-correlation) to 1 (a perfect classifier) with values around 0 corresponding to a random guess:
TN  TP−FP  FN
MCC ¼ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðTP þ FPÞðTP þ FN ÞðTN þ FP ÞðTN þ FN Þ

ð4Þ
where TP, TN, FP, and FN are defined above. The ROC
analysis describes a trade-off between the FPR and the

TPR for a classifier at varying decision threshold values.
The MCC and ROC are important metrics to help select
the best model considering the cost and the class distribution. The hyperparameters of the model, including the
number of features resulting in the best split, the minimum number of samples required to split an internal
node, and the minimum number of samples required to
be at a leaf node, are tuned with a grid search method.
The best set of hyperparameters maximizes both the
MCC and ROC.
Finally, the performance of the regression classifier is
evaluated with the mean squared error (MSE) and the
Pearson correlation coefficient (PCC) [66]. The MSE is a
risk function measuring the average of the squares of the
errors:

MSE ¼

N
1X
ðyb −y Þ2
N i¼1 i i

ð5Þ

where N is the total number of evaluation instances,
and ybi and yi are the predicted and actual values of i-th
instance, respectively. Further, the PCC is often
employed to assess the accuracy of point estimators by
measuring the linear correlation between the predicted
and actual values. Similar to the MCC, PCC ranges from
− 1 to 1, where − 1 is a perfect anti-correlation, 1 is a
perfect correlation, and 0 is the lack of any correlation.
It is calculated as:

PCC ¼

covð^y; yÞ
σ ^y σ y

ð6Þ

where covð^y; yÞ is the covariance matrix of the predicted and actual values, and σ ^y and σy are the standard
deviations of the predicted and actual values, respectively.

Results and discussion
SAscore prediction with eToxPred

The SAscore combining contributions from various molecular fragments and a complexity penalty, was developed to help estimate the synthetic accessibility of
organic compounds [62]. It ranges from 1 for molecules
easy to make, up to 10 for those compounds that are very
difficult to synthetize. The datasets used to train and validate the SAscore predictor, including FDA-approved,
DUD-E-active, NuBBE, and UNPD datasets, are highly
skewed, i.e., SAscore values are non-uniformly distributed
over the 1–10 range. For instance, Fig. 2 (solid gray line)
shows that as many as 28.3% of molecules in the original
dataset have a SAscore between 2 and 3. Therefore, a
pre-processing is needed to balance the dataset for a better performance of the SAscore predictor. Specifically, an
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Fig. 2 Resampling strategy to balance the dataset. The histogram shows the distribution of SAscore values across the training set before (solid
gray line) and after (dashed black line) the over/under-sampling

over/under-sampling procedure is employed by duplicating those cases with under-represented SAscore values
and randomly selecting a subset of over-represented instances. The over-sample ratio for the 1–2 range is 2.
The number of data points in the 2–5 range are uniformly under-sampled to 90,000, whereas those in the
5–6 range remain unchanged. For 6–7, 7–8, 8–9, and
9–10 ranges, the over-sample ratios are 2, 5, 20, and
100, respectively. Figure 2 (dashed black line) shows
that the over/under-sampled set contains more instances with low (1–2) and high (6–10) SAscore
values compared to the original dataset.
A scatter plot of the predicted vs. actual SAscore
values is shown in Fig. 3 for FDA-approved,
DUD-E-active, NuBBE, and UNPD datasets. Encouragingly, the cross-validated PCC (Eq. 6) across all four
datasets is as high as 0.89 with a low MSE (Eq. 5) of 0.81
(~ 4%) for the predicted SAscore. Next, we apply the
DBN predictor to individual datasets and analyze the distribution of the estimated SAscore values in Fig. 4. As expected, mostly synthetic molecules from the DUD-Eactive dataset have the lowest median SAscore of 2.9,
which is in line with values previously reported for catalogue and bioactive molecules from the World Drug Index
(http://www.daylight.com/products/wdi.html) and MDL
Drug Data Report (http://www.akosgmbh.de/accelrys/databases/mddr.htm) databases. The median SAscore for
FDA-approved drugs is 3.2 because in addition to synthetic and semi-synthetic compounds, this heterogeneous
dataset also contains natural products whose chemical

structures are generally more complex than the “standard”
organic molecules. Both datasets of natural products,
NuBBE and UNPD, have even higher median SAscore
values of 3.4 and 4.1, respectively. Further, similar to the
analysis of the Dictionary of Natural Products (http://
dnp.chemnetbase.com) conducted previously [62], natural
products employed in the present study have a characteristic bimodal distribution with two distinct peaks at a
SAscore of about 3 and 5. Finally, the median SAscore for
TCM is 4.1 concurring with those values calculated for
natural products. Interestingly, a number of TCM molecules have relatively high synthetic accessibility and the
shape of the distribution of the estimated SAscore values
is similar to that for the active compounds from the
DUD-E dataset. Overall, the developed DBN-based model
is demonstrated to be highly effective in estimating the
SAscore directly from binary molecular fingerprints.
Tox-score prediction with eToxPred

eToxPred was developed to quickly estimate the toxicity
of large collections of low molecular weight organic
compounds. It employs an ET classifier to compute the
Tox-score ranging from 0 (a low probability to be toxic)
to 1 (a high probability to be toxic). The primary dataset
to evaluate eToxPred consists of FDA-approved drugs,
considered to be non-toxic, and potentially hazardous
chemicals from the TOXNET database. Figure 5 shows
the cross-validated performance of eToxPred in the prediction of toxic molecules. The ROC curve in Fig. 5A
demonstrates that the ET classifier is highly accurate

Pu et al. BMC Pharmacology and Toxicology

(2019) 20:2

Page 8 of 15

Fig. 3 SAscore prediction for several datasets. The scatter plot shows the correlation between the predicted and true SAscore values for active
compounds from the Directory of Useful Decoys, Extended (DUD-E), FDA-approved drugs, and natural products from the NuBBE and UNPD
databases. The regression line is dashed black

Fig. 4 SAscore and Tox-score prediction for several datasets. Violin plots show the distribution of (a) SAscore and (b) Tox-score values across
active compounds from the Directory of Useful Decoys, Extended (DUD-E), FDA-approved drugs, natural products from the NuBBE and UNPD
databases, and traditional Chinese medicines (TCM)
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Fig. 5 Performance of eToxPred in the prediction of toxic molecules. (a) The receiver operating characteristic plot and (b) the Matthews
correlation coefficient (MCC) plotted as a function of the varying Tox-score. TPR and FPR are the true and false positive rates, respectively. Gray
areas correspond to the performance of a random classifier. eToxPred is first applied to the primary training set (FDA-approved / TOXNET, solid
black lines) to select the optimum Tox-score threshold. Then, the optimized eToxPred is applied to the independent testing set (KEGG-Drug and
T3DB, solid black stars)

with the area under the curve (AUC) of 0.82. According
to Fig. 5B, a Tox-score of 0.58 the most effectively discriminates between toxic and non-toxic molecules, yielding an MCC (Eq. 4) of 0.52. Employing this threshold
gives a high TPR of 0.71 at a low FPR of 0.19.
Next, we apply eToxPred with the optimized
Tox-score threshold to an independent dataset consisting of KEGG-Drug molecules, regarded as non-toxic,
and toxic substances obtained from T3DB. Despite the
fact that many of these compounds are unseen to the
ET classifier, eToxPred quite efficiently recognizes toxic
molecules. The MCC for the KEGG-Drug and T3DB
datasets is 0.35, corresponding to the TPR and FPR of
0.63 and 0.25, respectively. Table 2 shows that using the
ET classifier yields the best performance on this independent dataset compared to other machine learning
techniques. Even though RF is slightly more accurate
than ET against FDA-approved and TOXNET, the performance of ET is noticeably higher for KEGG-Drug and
T3DB. In addition, we tested two other classifiers, the
Linear Discriminant Analysis (LDA) [67] and Multilayer Perceptron (MLP) [68], however, their performance is generally not as high as those of RF and ET.
Furthermore, the results obtained for the TCM dataset show that ET has the lowest tendency to
over-predict the toxicity compared to other classifiers
(the last row in Table 2).

Switching to an independent dataset causes the performance of machine learning classifiers to deteriorate
on account of a fair amount of ambiguity in the training
and testing sets. To better understand the datasets, we
present a Venn diagram in Fig. 6. For instance,
FDA-approved and TOXNET share as many as 559 molecules, whereas the intersection of KEGG-Drug and
T3DB consists of 319 compounds. Further, 36 molecules
classified as non-toxic in the FDA-approved / TOXNET
dataset are labelled toxic in the KEGG-Drug / T3DB
dataset (162 compounds are classified the other way
around). As a result, the accuracy of both LDA and
MLP drops from 0.74 to 0.65, however, the accuracy of
ET only slightly decreases from 0.76 to 0.72, demonstrating the robustness of this classifier. Indeed, ET was
previously shown to be resilient to high-noise conditions
[43], therefore, we decided to employ this machine
learning technique as a default classifier in eToxPred.
We also apply eToxPred to evaluate the compound
toxicity across several datasets used to predict the synthetic accessibility. Not surprisingly, Fig. 4B shows that
FDA-approved drugs have the lowest median Tox-score
of 0.34. The toxicity of active compounds from the
DUD-E dataset is a bit higher with a median Tox-score
of 0.46. Molecules in both natural products datasets as
well as traditional Chinese medicines are assigned even
higher toxicity values; the median Tox-score is 0.56,
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Table 2 Performance of various machine learning classifiers to predict toxicity. The following classifiers are tested
Dataset

Metric

Toxicity classifiers
LDA

MLP

RF

ET

FDA-appr. /
TOXNET

ACC

0.745

0.744

0.760

0.756

KEGG-Drug /
T3DB

TCM

TPR / FPR

0.723 / 0.232

0.679 / 0.180

0.733 / 0.218

0.719 / 0.186

MCC

0.495

0.525

0.528

0.523

ACC

0.647

0.645

0.674

0.721

TPR / FPR

0.671 / 0.362

0.675 / 0.365

0.688 / 0.331

0.631 / 0.248

MCC

0.272

0.273

0.316

0.353

Tox-score

0.504 ± 0.013

0.537 ± 0.242

0.574 ± 0.143

0.552 ± 0.122

% toxic

63.9

61.8

68.5

59.7

Linear Discriminant Analysis (LDA), Multi-Layer Perceptron (MLP), Random Forest (RF), and Extra Trees (ET). Individual models are first trained and 5-fold crossvalidated against FDA-approved and TOXNET datasets and then applied to KEGG-Drug and T3DB as an additional validation against independent datasets. The
performance of toxicity classifiers on FDA-approved / TOXNET and KEGG-Drug / T3DB datasets is assessed with the accuracy (ACC, Eq. 1), true (TPR, Eq. 2) and
false (FPR, Eq. 3) positive rates, and the Matthews correlation coefficient (MCC, Eq. 4). The best performance across all models in terms of the highest ACC and
MCC values are highlighted in bold. Finally, the trained models are applied to estimate the toxicity of traditional Chinese medicines in the TCM dataset and the
average ± standard deviation Tox-score values as well as the percentage of predicted toxic molecules are reported

0.54, and 0.54 for NuBBE, UNPD, and TCM, respectively. These results are in line with other studies examining the composition and toxicology of TCM, for
instance, toxic constituents from various TCM sources
include alkaloids, glycosides, peptides, amino acids, phenols, organic acids, terpenes, and lactones [69].
Finally, the prediction of specific toxicities is assessed
against four independent datasets. Figure 7 and Table 3
show that the performance of eToxPred is the highest
against the AO and CD datasets with AUC values of
0.80. The performance against the remaining datasets,
CP (AUC of 0.72) and ED (AUC of 0.75), is only slightly
lower. These results are in line with benchmarking data
reported for other classifiers; for instance, eToxPred
compares favorably with different methods particularly
against the AO and ED datasets [30, 70]. Importantly,
the ET-based classifier employing molecular fingerprints

Fig. 6 Venn diagrams showing the overlap among various datasets.
FDA-approved and TOXNET are the primary training datasets,
whereas KEGG-Drug and T3DB are independent testing sets

turns out to be highly effective predicting not only the
general toxicity, but also specific toxicities as demonstrated for the carcinogenicity potency, cardiotoxicity,
endocrine disruption, and acute oral toxicity.
Composition of non-toxic compounds

Since eToxPred quite effectively estimates the toxicity of
small organic compounds from their molecular fingerprints, there should be some discernible structural attributes of toxic and non-toxic substances. On that
account, we decomposed FDA-approved and TOXNET
molecules into chemical fragments with eMolFrag [9] in
order to compare their frequencies in both datasets.

Fig. 7 Performance of eToxPred in the prediction of specific
toxicities. The receiver operating characteristic plots are shown for
Carcinogenicity Potency (CP), cardiotoxicity (CD), endocrine
disruption (ED), and acute oral toxicity (AO)
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Table 3 Performance of the Extra Trees classifier to predict
specific toxicities
Dataset

AUC

ACC

CP

0.721

0.722

CD

0.799

0.798

ED

0.750

0.744

AO

0.800

0.854

The following datasets are used: carcinogenicity potency (CP), cardiotoxicity
(CD), endocrine disruption (ED), and acute oral toxicity (AO). The performance
is assessed with the area under the curve (AUC) and the accuracy (ACC, Eq. 1)

Figure 8 shows a scatter plot of 698 distinct fragments
extracted by eMolFrag. As expected, the most common
moiety is a benzene ring, whose frequency is 0.27 in the
FDA-approved and 0.17 in TOXNET fragment sets. In
general, fragment frequencies are highly correlated with
a PCC of 0.98, however, certain fragments are more
often found in either dataset. To further investigate
these cases, we selected three examples of fragments
more commonly found in FDA-approved molecules,
represented by green dots below the regression line in
Fig. 8, and three counter examples of those fragments
that are more frequent in the TOXNET dataset, shown
as red dots above the regression line in Fig. 8. In

addition, the selected parent molecules for these fragments are presented in Fig. 9 (FDA-approved) and Fig. 10
(TOXNET).
Examples shown in Fig. 9 include piperidine (Fig. 9A),
piperazine (Fig. 9B), and fluorophenyl (Fig. 9C) moieties,
whose frequencies in FDA-approved/TOXNET datasets
are 0.069/0.026, 0.032/0.010, and 0.024/0.007, respectively. Nitrogen-bearing heterocycles, piperidine and piperazine, are of central importance to medicinal
chemistry [71]. Piperidine offers a number of important
functionalities that have been exploited to develop central
nervous system modulators, anticoagulants, antihistamines,
anticancer agents and analgesics [72]. This scaffold is the
basis for over 70 drugs, including those shown in Fig. 9A,
trihexyphenidyl (DrugBank-ID: DB00376), a muscarinic antagonist to treat Parkinson’s disease [73], donepezil (DrugBank-ID: DB00843), a reversible acetyl cholinesterase
inhibitor to treat Alzheimer’s disease [74], an opioid analgesic drug remifentanil (DrugBank-ID: DB00899) [75], and
dipyridamole (DrugBank-ID: DB00975), a phosphodiesterase inhibitor preventing the blood clot formation [76].
Similarly, many well established and commercially available drugs contain a piperazine ring as part of their molecular structures [77]. A wide array of pharmacological

Fig. 8 Composition of non-toxic and toxic compounds. The scatter plot compares the frequencies of chemical fragments extracted with
eMolFrag from FDA-approved (non-toxic) and TOXNET (toxic) molecules. The regression line is dotted black and the gray area delineates the
corresponding confidence intervals. Three selected examples of fragments more commonly found in FDA-approved molecules (piperidine,
piperazine, and fluorophenyl) are colored in green, whereas three counter examples of fragments more frequent in the TOXNET dataset
(chlorophenyl, n-butyl, and acetic acid) are colored in red
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Fig. 9 Composition of selected non-toxic compounds. Three examples of fragments more commonly found in FDA-approved molecules than in
the TOXNET dataset: (a) piperidine, (b) piperazine, and (c) fluorophenyl. Four sample molecules containing a particular moiety (highlighted by
green boxes) are selected from DrugBank and labeled by the DrugBank-ID

activities exhibited by piperazine derivatives make them
attractive leads to develop new antidepressant, anticancer,
anthelmintic, antibacterial, antifungal, antimalarial, and
anticonvulsant therapeutics [78]. Selected examples of
piperazine-based drugs presented in Fig. 9B, are antipsychotic fluphenazine (DrugBank-ID: DB00623), antiretroviral delavirdine (DrugBank-ID: DB00705), antihistamine
meclizine (DrugBank-ID: DB00737), and flibanserin (DrugBank-ID: DB04908) to treat hypoactive sexual desire disorder among pre-menopausal women [79]. All of these

compounds contain substituents at both N1- and
N4-positions, which concurs with the analysis of piperazine
substitution patterns across FDA-approved pharmaceuticals
revealing that 83% of piperazine-containing drugs are
substituted at both nitrogens, whereas only a handful have
a substituent at any other position [77].
Incorporating fluorine into drug leads is an established
practice in drug design and optimization. In fact, so-called
fluorine scan is often employed in the development of
drug candidates to systematically exploit the benefits of

Fig. 10 Composition of selected toxic compounds. Three examples of fragments more commonly found in the TOXNET dataset than in FDAapproved molecules: (a) chlorophenyl, (b) n-butyl, and (c) acetic acid. Four sample molecules containing a particular moiety (highlighted by red
boxes) are selected from ZINC and labeled by the ZINC-ID
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fluorine substitution [80]. As a result, an estimated
one-third of the top-performing drugs currently on the
market contain fluorine atoms in their structure [81]. The
presence of fluorine atoms in pharmaceuticals increases
their bioavailability by modulating pKa and lipophilicity, as
well as by improving their absorption and partitioning into
membranes [82]. Further, fluorination helps stabilize the
binding of a drug to a protein pocket by creating additional
favorable interactions, as it was suggested for the fluorophenyl ring of paroxetine (DrugBank-ID: DB00715) [83], a selective serotonin reuptake inhibitor shown in Fig. 9C. A
low metabolic stability due to cytochrome P450-mediated
oxidation can be mitigated by blocking metabolically unstable hydrogen positions with fluorine atoms [84], as exemplified by drug structures shown in Fig. 9C. Indeed, a
targeted fluorination of a nonsteroidal anti-inflammatory
drug flurbiprofen (DrugBank-ID: DB00712) helped prolong
its metabolic half-life [85]. Another example is cholesterol
inhibitor ezetimibe (DrugBank-ID: DB00973), in which two
metabolically labile sites are effectively blocked by fluorine
substituents [86]. Finally, replacing the chlorine atom with
a fluorine improves safety profile and pharmacokinetic
properties of prasugrel (DrugBank-ID: DB06209) compared
to other thienopyridine antiplatelet drugs, ticlopidine and
clopidogrel [87].
Composition of toxic compounds

Next, we selected three counter examples (red dots in
Fig. 8) of fragments frequently found in toxic substances, chlorophenyl, n-butyl, and acetic acid, whose
representative parent molecules are presented in Fig. 10.
For instance, the chlorophenyl moiety (Fig. 10A) is the constituent of p-chloroacetophenone (ZINC-ID: 896324) used
as a tear gas for riot control, crufomate (ZINC-ID:
1557007), an insecticide potentially toxic to humans, the
herbicide oxyfluorfen (ZINC-ID: 2006235), and phosacetim
(ZINC-ID: 2038084), a toxic acetylcholinesterase inhibitor
used as a rodenticide. Further, n-butyl groups (Fig. 10B) are
present in a number of toxic substances, including merphos
(ZINC-ID: 1641617), a pesticide producing a delayed
neurotoxicity in animals, n-butyl lactate (ZINC-ID:
1693581), an industrial chemical and food additive, diethylene glycol monobutyl ether acetate (ZINC-ID: 34958085)
used as solvents for cleaning fluids, paints, coatings and
inks, and n-butyl benzyl phthalate (ZINC-ID: 60170917), a
plasticizer for vinyl foams classified as toxic in Europe and
excluded from the manufacturing of toys and child care
products in Canada. The last example is the acetic acid
moiety (Fig. 10C) found in many herbicides, e.g. chlorfenac
(ZINC-ID: 156409), 4-chlorophenoxyacetic acid (ZINC-ID:
347851), and glyphosate (ZINC-ID: 3872713) as well as in
thiodiacetic acid (ZINC-ID: 1646642), a chemical used by
the material industry to synthesize sulfur-based electroconductive polymers.
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Conclusions
In this study, we developed a new program to predict the
synthetic accessibility and toxicity of small organic compounds directly from their molecular fingerprints. The estimated toxicity is reported as the Tox-score, a new machine
learning-based scoring metric implemented in eToxPred,
whereas the synthetic accessibility is evaluated with the
SAscore, an already established measure in this field. We
previously developed tools, such as eMolFrag and eSynth,
to build large, yet target-specific compound libraries for
virtual screening. eToxPred can be employed as a
post-generation filtering step to eliminate molecules that
are either difficult to synthesize or resemble toxic substances included in TOXNET and T3DB rather than
FDA-approved drugs and compounds listed by the
KEGG-Drug dataset. Additionally, it effectively predicts
specific toxicities, such as the carcinogenicity potency, cardiotoxicity, endocrine disruption, and acute oral toxicity. In
principle, this procedure could save considerable resources
by concentrating the subsequent virtual screening and molecular modeling simulations on those compounds having a
better potential to become leads.
Availability and requirements

Project name: eToxPred.
Project home page: https://github.com/pulimeng/
etoxpred
Operating system(s): Platform independent.
Programming language: Python 2.7+ or Python 3.5+.
Other requirements: Theano, numpy 1.8.2 or higher,
scipy 0.13.3 or higher, scikit-learn 0.18.1, OpenBabel 2.3.1,
CUDA 8.0 or higher (optional).
License: GNU GPL.
Any restrictions to use by non-academics: license
needed.
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